| P2093 | author name string | Peter J Jewesson | |
| | Richard S Slavik | |
| P2860 | cites work | Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy | Q24519008 |
| | Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections | Q28143533 |
| | Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections | Q28214070 |
| | A critical review of the fluoroquinolones: focus on respiratory infections | Q28215446 |
| | The therapeutic monitoring of antimicrobial agents | Q28356180 |
| | Linezolid: a review of its use in the management of serious gram-positive infections | Q33337060 |
| | Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance | Q33543130 |
| | Economics of home intravenous services | Q33560234 |
| | Cost-effectiveness and value of an IV switch | Q33560692 |
| | The economic potential of dual individualisation methodologies | Q33573956 |
| | Drug interactions and anti-infective therapies | Q33609402 |
| | Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, an | Q33691841 |
| | Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia | Q43410703 |
| | Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection | Q43415624 |
| | In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae | Q43552325 |
| | Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model | Q43617611 |
| | Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia | Q43633624 |
| | Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections | Q43823469 |
| | Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 |
| | Intravenous antibiotic therapy at home | Q44759043 |
| | Role for Dual Individualization with Cefmenoxime | Q44806786 |
| | Outpatient use of intravenous antibiotics. Introduction | Q45087969 |
| | Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics | Q45345504 |
| | Once-daily dosing of aminoglycosides | Q46860894 |
| | A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. | Q50509585 |
| | A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. | Q50509590 |
| | Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. | Q50522237 |
| | Monitoring serum vancomycin levels: climbing the mountain because it is there? | Q50525348 |
| | Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. | Q52081789 |
| | Pharmacodynamic interactions of antibiotics alone and in combination. | Q52239327 |
| | The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. | Q52695343 |
| | Pharmacodynamics of fluoroquinolones. | Q52994131 |
| | Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. | Q53945242 |
| | Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections | Q54297609 |
| | Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. | Q54344376 |
| | Clinical pharmacology and efficacy of vancomycin in pediatric patients. | Q54560810 |
| | Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis | Q67281381 |
| | Outpatient intravenous medications in the management of cystic fibrosis | Q68347294 |
| | Routine monitoring of serum vancomycin concentrations: waiting for proof of its value | Q69467058 |
| | Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides | Q69510690 |
| | Dual individualization: antibiotic dosage calculation from the integration of in-vitro pharmacodynamics and in-vivo pharmacokinetics | Q70073527 |
| | Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia | Q70386358 |
| | Relevance of antibiotic susceptibility testing for clinical practice | Q70669831 |
| | AUIC--the universal parameter within the constraint of a reasonable dosing interval | Q71697436 |
| | The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions | Q71821053 |
| | Mega-analysis of meta-analysis: an examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials | Q71842921 |
| | Intermittent and continuous ceftazidime infusion for critically ill trauma patients | Q72998867 |
| | The minimum single oral metronidazole dose for treating trichomoniasis: a randomized, blinded study | Q73372733 |
| | Comparison of vancomycin pharmacodynamics (1 g every 12 or 24 h) against methicillin-resistant staphylococci | Q73902210 |
| | Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis | Q74250668 |
| | The pharmacodynamics of beta-lactams | Q74802265 |
| | Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drug interactions | Q74815562 |
| | Continuous infusion of beta-lactam antibiotics | Q77634765 |
| | Pharmacokinetics and pharmacodynamics of outpatient intravenous antimicrobial therapy | Q77793516 |
| | Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms | Q33694513 |
| | Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods. | Q33695596 |
| | Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials | Q33714230 |
| | Pharmacokinetics and pharmacodynamics of fluoroquinolones | Q33770078 |
| | Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation | Q33770248 |
| | Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition | Q33834603 |
| | Effects of the antifungal agents on oxidative drug metabolism: clinical relevance | Q33858325 |
| | New pharmacodynamic parameters for antimicrobial agents | Q33885871 |
| | Macrolide drug interactions: an update | Q33895235 |
| | Pharmacodynamics of antibacterial drugs | Q33928642 |
| | Pharmacoeconomic considerations in the ambulatory use of parenteral cephalosporins | Q33938986 |
| | Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria | Q33976467 |
| | Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection | Q33977440 |
| | Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit | Q33979524 |
| | Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study | Q33982863 |
| | Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients | Q33982991 |
| | Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections | Q33983119 |
| | Feasibility of outpatient self-administration of parenteral antibiotics | Q34051558 |
| | Quinupristin-dalfopristin: an overview | Q34113774 |
| | Cost analysis of an adult outpatient parenteral antibiotic therapy (OPAT) programme. A Canadian teaching hospital and Ministry of Health perspective | Q34126824 |
| | What have we learned from pharmacokinetic and pharmacodynamic theories? | Q34183534 |
| | Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials | Q34235318 |
| | Linezolid for the treatment of resistant gram-positive cocci | Q34247278 |
| | Intravenous antibiotic therapy in an outpatient setting | Q34278448 |
| | Serum vancomycin concentrations: reappraisal of their clinical value | Q34330702 |
| | Is more than one quinolone needed in clinical practice? | Q34382546 |
| | A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses | Q34389944 |
| | Fluoroquinolone adverse effects and drug interactions | Q34408447 |
| | What in vitro models of infection can and cannot do. | Q34443398 |
| | What do we really know about antibiotic pharmacodynamics? | Q34443407 |
| | Pharmacodynamics of antiinfective therapy: taking what we know to the patient's bedside | Q34443415 |
| | Update: clinically significant cytochrome P-450 drug interactions | Q34456931 |
| | Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions | Q34458355 |
| | Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters | Q34459145 |
| | The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. | Q34747691 |
| | Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus | Q35111627 |
| | Pharmacodynamics of metronidazole determined by a time-kill assay for Trichomonas vaginalis | Q35117561 |
| | Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. | Q35121441 |
| | Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections | Q35123123 |
| | Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections | Q35123139 |
| | Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. | Q35136776 |
| | The postantibiotic effect. | Q35243982 |
| | Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosa | Q35647932 |
| | Intravenous-to-oral stepdown program: four years of experience in a large teaching hospital | Q35653373 |
| | Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis | Q35810298 |
| | Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients | Q35814807 |
| | Killing and regrowth of bacteria in vitro: a review. | Q37803210 |
| | Vancomycin Serum Concentration Monitoring : The Middle Ground is Best | Q38194525 |
| | Cost-effectiveness of outpatient parenteral antibiotics: a review of the literature | Q38233263 |
| | A randomised controlled trial of the costs of hospital as compared with hospital in the home for acute medical patients | Q38473499 |
| | Update on drug interactions with azole antifungal agents | Q38549824 |
| | Practice guidelines for community-based parenteral anti-infective therapy. ISDA Practice Guidelines Committee | Q38555438 |
| | Vancomycin therapeutic drug monitoring: is it necessary? | Q38566835 |
| | Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance | Q39828366 |
| | Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model. | Q40286774 |
| | Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins | Q40431109 |
| | Pharmacokinetic Optimisation of Vancomycin Therapy | Q40467559 |
| | The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents | Q40517235 |
| | Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital | Q40585005 |
| | Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. | Q40691752 |
| | Pharmacokinetic drug interactions with antimicrobial agents | Q40720380 |
| | Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides | Q40839182 |
| | A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients | Q40866399 |
| | Vancomycin administration and monitoring reappraisal | Q40923535 |
| | Antimicrobial resistance issues of the future | Q40930911 |
| | Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis | Q40988370 |
| | Evaluation of the use of cefuroxime and cefuroxime axetil in an intravenous-oral stepdown program | Q41054486 |
| | Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. | Q41058829 |
| | In vitro testing of antibiotics. | Q41120476 |
| | Pharmacokinetics and pharmacodynamics of antibiotics in otitis media | Q41148314 |
| | Mathematical Examination of Dual Individualization Principles (I): Relationships between AUC above MIC and Area under the Inhibitory Curve for Cefmenoxime, Ciprofloxacin, and Tobramycin | Q41149840 |
| | Pharmacokinetics and pharmacodynamics of newer fluoroquinolones | Q41254190 |
| | Pharmacokinetics and pharmacodynamics of newer macrolides | Q41435749 |
| | Outpatient parenteral antimicrobial-drug therapy | Q41593943 |
| | Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. | Q41696128 |
| | Systemic antifungal agents. Drug interactions of clinical significance | Q41725883 |
| | Self-administration of intravenous antibiotics: an efficient, cost-effective home care program. | Q41862104 |
| | Single or multiple daily doses of aminoglycosides: a meta-analysis | Q42145555 |
| | Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models | Q42169493 |
| | Comparative efficacy of amoxicillin-clavulanate, cloxacillin, and vancomycin against methicillin-sensitive and methicillin-resistant Staphylococcus aureus endocarditis in rats | Q42197204 |
| | Impact of Vancomycin Therapeutic Drug Monitoring on Patient Care | Q42278351 |
| | Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies | Q42553519 |
| | Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials | Q42671287 |
| P433 | issue | 9 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| | pharmacodynamics | Q725307 |
| P304 | page(s) | 793-817 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations | |
| P478 | volume | 42 | |